Bicara Therapeutics (BCAX) Non Operating Income (2023 - 2026)

Bicara Therapeutics has reported Non Operating Income for 4 years, with the latest figure at $4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 18.57% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at $16.9 million (up 1.27% YoY), and the FY2025 full-year result was $17.9 million, up 22.56% from the prior year.
• Non Operating Income for Q1 2026 stood at $4.1 million, up from $3.8 million in the prior quarter.
• The five-year high for Non Operating Income was $5.9 million in Q4 2024, with the low at -$13.3 million in Q3 2023.
• Historically, Non Operating Income has averaged $2.2 million across 4 years, with a median of $3.8 million in 2025.
• Annual changes were most pronounced in 2024 — Non Operating Income jumped 368.53% — and 2025, when it tumbled 35.41%.
• Bicara Therapeutics' Non Operating Income stood at $1.3 million in 2023, then surged by 368.53% to $5.9 million in 2024, then plunged by 35.41% to $3.8 million in 2025, then climbed by 7.76% to $4.1 million in 2026.
• The last three Non Operating Income figures came in at $4.1 million (Q1 2026), $3.8 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.